Latest News for: amisulpride

Edit

Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride ...

Nasdaq Globe Newswire 30 Apr 2024
Preliminary results from the Company’s ongoing Phase 2/3 study expected in the first half of 2025. Preliminary results from the Company’s ongoing Phase 2/3 study expected in the first half of 2025 ... .
Edit

Eagle Pharmaceuticals To Present Abstract On Post-Hoc Analysis Of Amisulpride At The 77Th PGA (Postgraduate ...

MENA FN 06 Dec 2023
(MENAFN - GlobeNewsWire - Nasdaq) -- BARHEMSYS– (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration (–FDA–) for rescue treatment of ... .
Edit

Risk adjusted net present value: What is the current valuation of Sumitomo Pharma’s Amisulpride?

Offshore Technology 01 Aug 2023
Amisulpride is a small molecule commercialized by Sumitomo Pharma, with a leading Phase III program in Bipolar Disorder (Manic Depression) ... The revenue for Amisulpride is expected ... Amisulpride Overview.
  • 1

Most Viewed

×